

















1204Comparison of Outcomes after HLA-Matched Sibling
and Unrelated Donor Transplantation for Children with
High-Risk Acute Lymphoblastic Leukemia
Mei-Jie Zhang,1 Stella M. Davies,2 Bruce M. Camitta,3 Brent Logan,1
Karin Tiedemann,4 Mary Eapen1We compared outcomes after 94 HLA-matched sibling, 168 unrelated donor bone marrow (BM; n 5 81
matched and n 5 88 mismatched), and 86 cord blood transplantations in patients age 1 to 15 years with
acute lymphoblastic leukemia (ALL) in second complete remission (CR). All patients had their first BM relapse
within 3 years from diagnosis. Cox regression models were constructed to examine for differences in trans-
plant outcome by donor source. Risks of grade 2 to 4 acute graft-versus-host disease (aGVHD) and chronic
graft-versus-host disease (cGVHD), when compared to HLA-matched sibling transplants, were higher after
matched unrelated donor BM (relative risk [RR], 2.42; P5 .001; RR, 5.12; P\.001, respectively), mismatched
BM (RR, 3.24; P\.001; RR, 5.19; P\.001, respectively), and cord blood (RR, 2.67; P\.001; RR, 2.54; P5.024,
respectively) transplants. Although nonrelapse mortality was higher after transplantation of mismatched un-
related donor BM and cord blood, there were no differences in leukemia-free survival (LFS) between HLA-
matched sibling and anyof the unrelated donor transplantations. The 3-year probabilities of LFSwere 50%after
HLA-matched sibling and 44% after matched unrelated BM, and 44% after mismatched unrelated BM and 43%
aftercordblood transplantation.Ourobservations support transplantationofBMorcordblood froma suitably
matched unrelated donor or cord blood for patients without an HLA-matched sibling with ALL in second CR.
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The last 40 years have seen dramatic improve-
ments in survival for children with acute lymphoblastic
leukemia (ALL), such that cure rates with chemother-
apy now approach 85% [1]. Nevertheless, approxi-
mately 20% of the children will relapse. The
outcomes of the 70% of children with relapsed ALL
who present within 3 years are worse, which makes1Center for International Blood and Marrow Transplant
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6/j.bbmt.2012.01.007them high risk [2]. With current salvage protocols,
85% of these children achieve a second complete
remission (CR). However, in children with high-risk
relapses who attain a second CR, durable remission
is only from 0% to 25% with chemotherapy alone
[3,4]. There are data to support the hypothesis that
long-term leukemia-free survival (LFS) is superior af-
ter allogeneic hematopoietic stem cell transplant. The
Berlin-Frankfurt-Munster Group compared outcomes
after matched unrelated donor bone marrow trans-
plantation (BMT) and continuing chemotherapy [4].
These authors observed superior LFS in children
with high-risk ALL after unrelated donor BMT com-
pared to chemotherapy alone, 44% versus 0%, P \
.001, respectively. More recently, the Children’s On-
cology Group and the Center for International Blood
and Marrow Transplant Research (CIBMTR) com-
pared LFS after HLA-matched sibling BMT and che-
motherapy alone in children who relapsed within 3
years from diagnosis and attained a secondCR.Higher
LFS was observed after transplantation (41%) than
with chemotherapy (23%) at 8 years, P\ .001 [5].
Because only 30% of patients who might benefit
from transplantation have amatched sibling, identifying
Biol Blood Marrow Transplant 18:1204-1210, 2012 1205Transplantation for Children with Acute Lymphoblastic Leukemiaa suitably matched donor for transplantation remains
a challenge. For white people, the probability of identi-
fying a suitably matched unrelated BM donor is about
70%; for non-whites, the likelihood is much less,
about 30%. Many more patients are able to find a suit-
able donor cord blood unit because the immunologic
naivety of cord blood lymphocytes allows for successful
transplantation across HLA barriers not possible with
unrelated donor BM grafts. This has led to the increas-
ing use of cord blood grafts instead of BM for unrelated
donor transplantation. Cord blood grafts now account
for approximately 40% of pediatric allogeneic trans-
plantations in the United States. Unrelated cord blood
units are readily available, as they are already tested
and banked, an advantage when considering transplan-
tation for patients who attain a secondCR after early re-
lapse. The CIBMTR and the Eurocord Registry have
compared outcomes after unrelated donor BMT and
cord blood transplantation for acute leukemia in chil-
dren [6,7]. Although hematopoietic recovery is slower
and nonrelapse mortality is higher after cord blood
transplantation, long-term LFS is comparable after
matched unrelated donor BM and mismatched cord
blood transplantation.
Stem cell transplant from anHLA-matched sibling
is the accepted standard treatment for children with
high-risk ALL in second CR. The higher risk of non-
relapse mortality associated with unrelated BM and
cord blood transplantation raises anxiety among pedi-
atric oncologists when considering alternative donor
transplantation for these patients. On the other hand,
it is sometimes suggested that a more mismatched
stem-cell source will give better disease control, and
that a matched sibling donor should not be used for
the most aggressive leukemias. To address this con-
cern, we compared transplant outcomes after unre-
lated donor BM and cord blood transplantation to
those after HLA-matched sibling BM transplantation
in children with ALL who relapsed within 3 years
from diagnosis and attained a second CR. Unrelated
adult donors and cord blood grafts were selected using
current selection criteria for these graft types, allowing
the opportunity to evaluate and compare transplant
outcomes as practiced in the current era.PATIENTS AND METHODS
Data Collection
Data regarding patient, disease, and transplanta-
tion characteristics and outcomes were obtained
from the CIBMTR, a voluntary working group of
over 400 transplantation centers worldwide that pro-
vide data prospectively on consecutive transplanta-
tions to a Statistical Center at the Medical College of
Wisconsin. All patients are followed longitudinally un-
til death or loss to follow-up. Use of standardized datacollection forms, biannual training of clinical research
coordinators at participating centers, computerized
error checks, review of submitted data by physicians,
and on-site audits ensured data quality. This study
was approved by The Institutional Review Board of
the Medical College of Wisconsin.
Inclusion Criteria
Patients with ALL age 1 to 15 years and in second
CR at transplantation were eligible if their first relapse
occurred within 3 years from diagnosis. The sites of
relapse were bone marrow (BM) alone or BM plus
extramedullary involvement. Transplants occurred be-
tween 1997 and 2005. BM donors were HLA-matched
siblings or unrelated adult donors. Cord blood grafts
were from unrelated donors. There were too few re-
cipients of peripheral blood grafts and were therefore
excluded. Unrelated adult donors were matched to
the patient at HLA-A, HLA-B, HLA-C, and HLA-
DRB1 at the allele-level (all of 8 HLA match) or mis-
matched at 1-loci or 2-loci. Patients who received cord
blood units were matched for at least 4 of 6 HLA-loci
(HLA-A, HLA-B [antigen-level], and HLA-DRB1
[allele-level]) and had a post-thaw total nucleated cell
dose $2.5  107/kg of patient body weight. All pa-
tients received myeloablative conditioning regimens
and calcinurin inhibitor graft-versus-host disease
(GVHD) prophylaxis.
Endpoints
Neutrophil recovery was defined as achieving an
absolute neutrophil count $0.5  109/L for 3 consec-
utive days and platelet recovery $20  109/L unsup-
ported for 7 days. Acute and chronic (aGVHD and
cGVHD) were graded using standard criteria [8,9].
Nonrelapse mortality was defined as death occurring
in CR, relapse, as recurrence of disease at any site,
and LFS, the likelihood of surviving in CR after
transplantation.
Statistical Analysis
Patient, disease, and transplantation characteristics
were compared among the 3 groups using the chi-
square test for categorical variables (Table 1). The
probability of LFS was calculated using the Kaplan-
Meier estimator [10]. For LFS, relapse or death from
any cause was considered an event, and patients surviv-
ing in complete continuous remission were censored at
the last follow-up. The cumulative incidence estimator
was used to calculate the probability of neutrophil and
platelet recovery, aGVHD and cGVHD, and relapse
and nonrelapse mortality [11]. For hematopoietic re-
covery, and aGVHD and cGVHD, death without an
event was the competing risk; patients who were alive
without the event were censored at last follow-up.
For nonrelapse mortality, relapse was the competing
event, and for relapse, nonrelapse mortality was the
Table 1. Patient, Disease, and Transplant Characteristics
Characteristics Matched Sibling BM Unrelated BM Cord Blood P value
Number of patients 94 168 86
Age at transplantation, years <.001
1-10 67 (71) 129 (77) 83 (96)
11-15 27 (29) 3 (23) 3 (4)
Male sex 52 (55) 104 (62) 49 (57) .51
Race <.001
White 52 (55) 132 (79) 63 (73)
Other 42 (45) 36 (21) 23 (27)
Performance score at transplantation .81
90-100 80 (85) 133 (79) 70 (81)
<90 14 (15) 23 (14) 15 (18)
Unknown 0 12 (7) 1 (1)
Recipient CMV serostatus .25
Seropositive 44 (47) 64 (38) 39 (46)
Seronegative 49 (52) 104 (62) 46 (53)
Unknown 1 (1) 0 (0) 1 (1)
ALL subtype
B-lineage 72 (77) 120 (71) 64 (74) .24
T-lineage 14 (15) 19 (11) 7 (8)
Unclassified/other 8 (8) 29 (17) 15 (18)
Cytogenetics .24
Normal 29 (31) 36 (21) 19 (22)
High risk 5 (5) 18 (11) 6 (7)
Intermediate risk 34 (36) 46 (27) 35 (41)
Low risk 10 (11) 25 (15) 11 (13)
Unknown 16 (17) 43 (26) 15 (17)
Year of transplantation .002
1997-2001 70 (74) 92 (55) 44 (51)
2002-2005 24 (26) 76 (45) 42 (49)
Conditioning regimen <.001
TBI + other 92 (98) 156 (93) 73 (85)
Bu + other (Cy or melphalan) 2 (2) 12 (7) 13 (15)
GVHD prophylaxis 0.005
Cyclosporine +/2 other agents 92 (98) 147 (88) 82 (95)
Tacrolimus +/2 other agents 2 (2) 21 (12) 4 (5)
BM indicates bone marrow; CMV, cytomegalovirus; ALL, acute lymphoblastic leukemia; TBI, total body irradiation; Bu, busulfan; Cy, cyclophosphamide;
GVHD, graft-versus-host disease.
Values are n (%).
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tervals (CIs) were calculated with the use of a log trans-
formation.
Multivariate analyses were performed using Cox
regression models [12]. Models were built with the
use of forward stepwise selection, and variables that at-
tained a P value of #.05 were held in the model. We
created 4 treatment groups that incorporated donor,
graft, and donor–recipient HLA match and included
them in all steps of model building regardless of level
of significance: HLA-matched sibling transplantation,
the baseline group for all comparisons; all of 8 HLA-
matched adult unrelated donor BM transplants;
HLA-mismatched adult unrelated donor BM trans-
plants; and unrelated cord blood transplants. Other
variables considered include: patient gender (male ver-
sus female), performance score at time of transplant
(90-100 versus\90), age at transplantation (1-10 ver-
sus 11-15 years), recipient cytomegalovirus (CMV)
serostatus (positive versus negative), race (white versus
other), leukemia subtype (B-lineage versus T-lineage),
cytogenetics (normal versus high-risk versus
intermediate-risk versus low-risk), National CancerInstitute (NCI) risk group (standard versus high), dura-
tionof firstCR (\18months versus 18-36months), and
year of transplantation (1997-2002 versus 2003-2007).
All variables satisfied the proportional hazards assump-
tion, and there were no first-order interactions de-
tected. All P values are 2 sided. All analyses were done
with SAS version 9.1 (SAS Institute Inc., Cary, NC).RESULTS
Patient and Transplantation Characteristics
Patient, disease, and transplantation-related char-
acteristics are shown inTable 1. Ninety-four recipients
of HLA-matched sibling donor transplantations, 168
recipients of unrelated donor BM transplants, and 86
recipients of unrelated cord blood transplants were eli-
gible. Most patients had B-lineage ALL. All patients
had first CR duration less than 36 months and, there-
fore, were considered ‘‘high risk.’’ One hundred forty-
one patients (41%) had first CR duration less than 18
months. Cytogenetic risk was defined as follows: low
risk included hyperdiploid (chromosome number of
Table 2. Univariate Probabilities of GVHD, Nonrelapse Mortality, Relapse, LFS, and Overall Survival
Outcome Matched Sibling BM (95% CI) Unrelated Matched BM (95% CI) Unrelated Mismatched BM (95% CI) Cord Blood (95% CI) P value
Acute GVHD <.001
100 days 22 (15-31) 46 (35-57) 57 (47-66) 50 (39-60)
Chronic GVHD <.001
3 years 10 (5-17) 36 (25-46) 35 (25-45) 20 (13-29)
Nonrelapse mortality .127
3 years 13 (7-20) 21 (13-31) 27 (18-36) 29 (19-38)
Relapse .900
3 years 37 (27-47) 35 (24-45) 29 (20-39) 30 (21-40)
LFS .614
3 years 50 (40-60) 44 (33-55) 44 (34-55) 43 (32-53)
Overall survival .724
3 years 54 (43-64) 49 (37-59) 47 (36-58) 44 (33-54)
GVHD indicates graft-versus-host disease; LFS, leukemia-free survival; BM, bone marrow; CI, confidence interval.
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high risk included hypodiploidy (chromosome number
of 45 or less), translocation (9; 22); and intermediate
risk included all other abnormalities. The NCI risk
groups were defined as follows: Patients with a WBC
less than 50,000 and between the ages of 1 and 9 years
at diagnosis were classified as standard risk. The re-
maining patients were in the high-risk NCI risk group.
Recipients of HLA-matched sibling and unrelated do-
nor transplants were similar in gender, pretransplanta-
tion performance score, recipient CMV serostatus,
cytogenetics, NCI risk group, and leukemia subtype.
However, recipients of unrelated donor transplanta-
tionsweremore likely to bewhite and to undergo trans-
plantations more recently. Recipients of unrelated
donor BM grafts were more likely to receive
tacrolimus-containing GVHD prophylaxis. Although
the median ages of HLA-matched sibling, adult unre-
lated donorBM, and cordblood recipientswere 8 years,
7 years, and 6 years, respectively, very few cord blood
recipients were older than 10 years. Eighty-one recipi-
ents (48%) of adult unrelated donor BMwere matched
at the allele level at HLA-A, HLA-B, HLA-C, and
HLA-DRB1; 87 recipients (52%) were mismatched at
1-loci or 2-loci. Eleven cord blood recipients (13%)
were matched at HLA-A, HLA-B (antigen-level),
HLA-DRB1 (allele-level); 34 (40%) were mismatched
at 1-loci; and 41 (48%) were mismatched at 2-loci.
The median follow-up of patients was 6 years after
HLA-matched sibling and4 years after unrelated donor
BM or cord blood transplant.Neutrophil and Platelet Recovery
The day-42 incidence of neutrophil recovery was
98% (95% CI, 91%-99%) after HLA-matched sibling
and 97% (95% CI, 93%-99%) after unrelated donor
BM transplant. Neutrophil recovery was significantly
lower after cord blood transplantation at 83% (95%
CI, 72%-90%), P \ .001. Cumulative incidents of
platelet recovery were lower after unrelated donor
BM and cord blood transplant. The day-100 incidenceof platelet recovery after unrelated donor BM and cord
blood transplant were 80% (95% CI, 73%-86%) and
65% (95% CI, 55%-76%), respectively, compared
with 92% (95% CI, 86%-97%), P \ .001, after
HLA-matched sibling transplantation. There were
no differences in neutrophil or platelet recovery
among recipients of matched and mismatched unre-
lated donor BM transplants.
Acute and Chronic GVHD
The univariate probabilities of grades 2 to 4
aGVHD and cGVHD are shown in Table 2. The
day-100 incidence of aGVHD was higher in matched
and mismatched unrelated donor BM and cord blood
transplants. In multivariate analysis, grade 2 to 4
aGVHD risks were higher after any unrelated donor
transplantation compared to HLA-matched sibling
transplantation (Table 3). Acute GVHDwas more fre-
quent in patients with performance scores #90 and
this effect was independent of donor type (relative
risk [RR], 1.54; 95%CI, 1.02-2.32; P5 .038). Chronic
GVHD risk was also higher after any unrelated donor
transplantation compared to HLA-matched sibling
transplantation (Table 3).
Nonrelapse Mortality and Relapse
The univariate probabilities of nonrelapse mortal-
ity and relapse are shown in Table 2 and Figure 1.
Compared to HLA-matched sibling transplants, non-
relapse mortality risks were higher after mismatched
unrelated donor BM and cord blood transplantation
but not after matched unrelated donor BM transplan-
tation (Table 3). Leukemic recurrence occurred in 113
of 348 patients. In multivariate analysis, risks of leuke-
mic relapse were similar after HLA-matched sibling
and any unrelated donor transplantation (Table 3).
Other known risk factors, such as cytogenetics, NCI
risk group, and ALL subtype, were not associated
with relapse in the current analysis. We also tested
for the effect of duration of first CR to determine
whether relapse risks differed among patients with
Table 3. Multivariable Analysis of Acute and Chronic GVHD, Nonrelapse Mortality, Relapse, LFS, and Overall Survival
Number* RR (95% CI) P value
Grade 2-4 aGVHD
URD matched BM versus sibling 37/80 versus 21/94 2.43 (1.42-4.16) .001
URD MM BM versus sibling 50/88 versus 21/94 3.24 (1.94-5.41) <.001
Cord blood versus sibling 44/86 versus 21/94 2.67 (1.60-4.50) <.001
Chronic GVHD
URD matched BM versus sibling 29/80 versus 9/94 5.12 (2.42-10.84) <.001
URD MM BM versus sibling 31/88 versus 9/94 5.19 (2.47-10.92) <.001
Cord blood versus sibling 17/86 versus 9/94 2.54 (1.13-5.70) .024
Nonrelapse mortality
URD matched BM versus sibling 17/80 versus 13/94 1.61 (0.78-3.32) .195
URD MM BM versus sibling 23/88 versus 13/94 1.98 (1.01-3.92) .048
Cord blood versus sibling 24/86 versus 13/94 2.18 (1.11-4.30) .024
Relapse
URD matched BM versus sibling 28/80 versus 34/94 1.09 (0.66-1.79) .745
URD MM BM versus sibling 26/88 versus 34/94 0.89 (0.53-1.48) .645
Cord blood versus sibling 25/86 versus 34/94 0.95 (0.57-1.59) .839
Treatment failure
URD matched BM versus sibling 45/80 versus 47/94 1.23 (0.82-1.85) .322
URD MM BM versus sibling 49/88 versus 47/94 1.19 (0.80-1.78) .388
Cord blood versus sibling 49/86 versus 47/94 1.30 (0.87-1.94) .202
Overall mortality
URD matched BM versus sibling 43/80 versus 47/94 1.17 (0.77-1.77) .458
URD MM BM versus sibling 45/88 versus 47/94 1.11 (0.74-1.68) .607
Cord blood versus sibling 46/86 versus 47/94 1.257 (0.84-1.89) .271
GVHD indicates graft-versus-host disease; LFS, leukemia-free survival; RR, relative risk; CI, confidence interval; aGVHD, acute GVHD; URD, unrelated
donor; BM, bone marrow; MM, mismatched.
*Number of events/number of evaluable patients.
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those with longer duration first CR (18-36 months)
and did not find a statistically significant difference
(RR, 0.78; 95% CI, 0.54-1.14; P 5 .19).Leukemia-Free and Overall Survival
The univariate probabilities of leukemia-free and
overall survival are shown in Table 2. In multivariate
analysis, there were no differences in treatment failure
(relapse or death; inverse of LFS; Figure 2) or overall
mortality after HLA-matched sibling and matched or
mismatched unrelated donor BM or cord blood trans-
plantation (Table 3). Other known risk factors, such as
cytogenetics, NCI risk group, duration of first CR, and
ALL subtype, were not associated with leukemia-free
and overall survival in the current analysis. One hun-
dred eighty-one patients died after receiving a trans-
plant (50% of HLA-matched sibling transplant
recipients [47 of 94] and 52% of unrelated donor trans-
plant recipients [134 of 254]). Recurrent leukemia was
the most common cause of death accounting for 65%
of deaths after HLA-matched sibling transplantation
and 50% of deaths after unrelated donor transplanta-
tion. GVHD-related deaths were more likely after
unrelated donor transplantation compared with HLA-
matched sibling transplantation (13% versus 2%).
The proportion of deaths attributed to infection
(10% versus 6%), interstitial pneumonitis/acute respi-
ratory distress syndrome (12% versus 15%), organ fail-
ure (8% versus 7%), and other miscellaneous causes(6% versus 4%) were not different after unrelated do-
nor and HLA-matched sibling transplantations.DISCUSSION
There is general agreement that for children with
high-risk ALL in second CR, hematopoietic stem
cell transplantation is superior to chemotherapy alone.
The lack of a matched sibling for most patients and the
higher risk of nonrelapse mortality after mismatched
unrelated donor BM or cord blood transplantation
remain obstacles to referral for transplantation.
Consequently, the primary objective of the current
analysis was to determine whether outcomes after
HLA-matched sibling BM or cord blood transplanta-
tion are comparable to those after HLA-matched sib-
ling BM transplantation in a group of patients at very
high risk of further relapse and death without trans-
plantation. Despite higher risks of aGVHD and
cGVHD after unrelated donor transplantation and
higher nonrelapse mortality after mismatched
unrelated donor BM and cord blood transplantations,
the 3-year LFS was comparable after matched or mis-
matched unrelated donor BM, cord blood, and HLA-
matched sibling donor transplantation. The pattern of
treatment failure differed by donor type. Whereas
nonrelapse mortality was higher after unrelated donor
transplantation, we observed a higher, but not statisti-
cally significant, risk of relapse after HLA-matched
sibling donor transplantation. Others have also shown
Figure 2. Probabilities of leukemia-free survival (LFS) by hematopoi-
etic stem-cell source and donor–recipient HLA matching: group A 5
HLA-matched sibling bone marrow (BM), group B5matched unrelated
BM, group C 5 mismatched unrelated BM, and group D 5 cord blood
transplants.
Figure 1. (A) Probabilities of nonrelapse mortality by hematopoietic
stem-cell source and donor–recipient HLA matching: group A 5
HLA-matched sibling bone marrow (BM), group B5matched unrelated
BM, group C 5 mismatched unrelated BM, and group D 5 cord blood
transplants. (B) Probabilities of relapse by hematopoietic stem-cell
source and donor–recipient HLA matching: group A 5 HLA-matched
sibling BM, group B 5 matched unrelated BM, group C 5 mismatched
unrelated BM, and group D 5 cord blood transplants.
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lated donor BM and cord blood transplantation for
acute leukemia in children [6,7]. All patients in the
current analysis experienced early relapse with
duration of first CR\36 months. Our data does not
indicate differences in rates of relapse, LFS,
and overall survival in patients whose duration of first
CR was less than 18 months compared with those
with duration of first CR between 18 and 36 months.
In the current analysis, for the unrelated donor
BMgroup, significant differences in nonrelapsemortal-
ity risks were seen only after mismatched unrelated
donor BM, not in the matched unrelated BM,
compared to HLA-matched sibling transplantation.
Donor–recipient HLA matching, when considering
transplantation of BM from an unrelated adult donor,
is important, and currently, the ideal donor is one
matched to the recipient at a minimum of HLA-A,
HLA-B, HLA-C, and HLA-DRB1 using high-resolu-
tion (allele-level) typing [13]. In the absence of
a matched adult unrelated donor, cord blood grafts
are an acceptable option. Compared with HLA-
matched sibling BM transplantations, LFS is similar af-
ter unrelated cord blood transplantation, and consistent
with a smaller series froma single institution [14]. In thecurrent analysis, we included only transplantations per-
formedwith cordbloodunits that containedaminimum
infused total nucleated cell dose$2.5 107/kg, the cur-
rent clinical standard for this type of graft. Despite this,
neutrophil recovery was slower, and the likelihood of
recovery lower, compared with HLA-matched sibling
transplantation. In general, early nonrelapse mortality
is higher after mismatched cord blood transplantation.
Strategies to overcome the cell dose limitation include:
transplantation of 2 cord blood units to achieve the
desired cell dose, ex vivo expansion of cord blood
cells, and co-infusion of haplo-identical cells [15-21].
Additionally, the larger inventory and preferential
banking of larger units allow for selection of cord
blood units that are matched or 1-locus mismatched to
the recipient. Nonrelapse mortality rates after matched
and 1-locusmismatched cord blood units with cell dose
.3  107/kg have been shown to be similar [7].
We did not observe significant differences in re-
lapse risks after unrelated donor and HLA-matched
sibling transplantation. This is not surprising because
others have shown that posttransplantation adoptive
immunotherapy with donor leukocyte infusion or nat-
ural killer cells are disappointing for treating relapsed
ALL. A strong graft-versus-leukemia effect may be ab-
sent or minimal for ALL using these techniques
[22,23].
The relative efficacy of unrelated donor and HLA-
matched sibling transplantation did not differ by pa-
tient age or other known prognostic factors such as
ALL subtype, cytogenetics, and NCI risk group. The
current analysis includes only patients with ALL in
second CR who had had a BM relapse within 3 years
from diagnosis. Further, all patients received T cell–
replete grafts, myeloablative conditioning regimens,
and calcineurin inhibitor GVHD prophylaxis.
Whereas the homogenous study population was an
advantage with respect to studying transplant out-
comes, the homogeneity may have prevented us from
1210 Biol Blood Marrow Transplant 18:1204-1210, 2012M.-J. Zhang et al.identifying disease-specific factors known to influence
long-term LFS. It is plausible that factors predictive of
long-term survival at diagnosis may no longer be rele-
vant after first relapse. Nevertheless, these known risk
factors and chemotherapy received before transplanta-
tion may have influenced the likelihood of achieving
and sustaining second CR.
Although randomized clinical trials are the ‘‘gold
standard’’ for comparing different treatment strategies
including donor selection, in the absence of such a trial,
we have used data collected by a large transplantation
registry to perform a carefully controlled analysis.
A randomized controlled trial is unlikely to be per-
formed. The logistics of randomizing patients to dif-
ferent donor sources is formidable because different
processes are needed to identify and procure a related
donor, an unrelated adult donor, or a cord blood graft.
Because very few patients will have a suitably matched
unrelated adult donor and a banked cord blood unit
available to them, accrual to such a trial would take
many years. If a biologic randomization were to be per-
formed such that any patient with an HLA-matched
sibling would be assigned to that arm, ethical consider-
ations such as the rationale of subjecting a patient with
a matched unrelated adult donor to mismatched cord
blood transplant could be an impediment to accrual.
Our findings suggest that all patients with ALL with
early relapse who attain a second CR should proceed
to BMT with the best available donor source.ACKNOWLEDGMENT
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